Company news

Zai Lab Ltd. news in 2026

Zai Lab Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Next Day Disclosure Return

October 28, 2026

Voluntary announcement - closing of the private placement of american depositary shares

October 28, 2026

Notice of audit committee action

October 23, 2026

Inside information - update on first data from global phase 1B clinical trial

October 23, 2026

Overseas regulatory announcement - form 8-K

October 23, 2026

Private placement of american depositary shares and issuance of underlying shares under general mandate

October 22, 2026

Charter of the nominating and corporate governance committee

October 20, 2026

Monthly return of equity issuer on movements in securities for the month ended 30 September 2026

October 5, 2026

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

July 22, 2026

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

June 8, 2026

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)

May 11, 2026

Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates

May 7, 2026

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

April 22, 2026

Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases

April 18, 2026

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

April 17, 2026

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

April 15, 2026

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

April 1, 2026

Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)

March 17, 2026

Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

February 26, 2026

Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026

February 10, 2026

Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference

January 13, 2026

Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors

January 6, 2026

Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Calls in 2026

Decks in 2026